Exogenous NO was shown to effectively reduce systemic hyperinflammation, oxidative stress through inhibition of IDO enzymatic activity, downregulation of AT-2 and its receptors, and inactivation of cGMP-mediated PDE5 pathway among severe COVID-19 patients. The gene discussed is PDE5A; the disease is COVID-19.